> > Diagnosis Codes

HEMOPHILIA A DIAGNOSIS CODES

HEMOPHILIA A DIAGNOSIS CODES

It may be appropriate to use one of the hemophilia A ICD codes below for patients treated with Esperoct®.

Esperoct® package

Claim forms typically require an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or Tenth Revision (ICD-10-CM) diagnosis code.

Questions about Esperoct®? We’re here to help.

Enter your zip code to find a Novo Nordisk Representative.

How to order Esperoct®.

Esperoct® ordering

Operators are always available to assist with your product order.

See How to Order

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Register

Also available from Novo Nordisk:

NovoSeven® RT coagulation factor VIIa (recombinant) logo

Visit website
Prescribing Information

Rebinyn® coagulation Factor IX (recombinant) GlycoPEGylated logo

Visit website
Prescribing Information

Novoeight® antihemophilic factor (recombinant) logo

Visit website
Prescribing Information

Visit website
Prescribing Information

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information

References:

  1. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). https://www.cdc.gov/nchs/icd/icd9cm.htm. Last reviewed November 6, 2015. Accessed August 15, 2019.
  2. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (2020 release of ICD-10-CM). http://www.cdc.gov/nchs/icd/icd10cm.htm#icd2016. Last reviewed August 5, 2019. Accessed August 15, 2019.